French software giant Dassault Systèmes is in advanced discussions to acquire ArisGlobal, a Miami-founded life sciences software company owned by Nordic Capital, for approximately $2 billion, according to the Financial Times. No deal has been finalized, and negotiations could still fall through.
If completed, the transaction would rank as Dassault’s second-largest acquisition in its history, behind only its $5.8 billion purchase of Medidata Solutions — a clinical trial software company — in 2019. That deal, which remains the defining move of Dassault’s push into life sciences, gave the company a major foothold in the pharmaceutical R&D software market. An ArisGlobal deal would significantly deepen that position.
ArisGlobal, founded in 1987 and now headquartered in Waltham, Massachusetts, develops end-to-end SaaS software for the pharmaceutical drug development lifecycle. Its flagship LifeSphere platform covers pharmacovigilance and drug safety, regulatory information management, clinical data management, medical affairs, and quality management — effectively spanning the full continuum of functions a drug developer needs from clinical trial through market approval and post-market surveillance. The company counts more than 300 life sciences organizations as clients, including 30 of the top 50 global biopharmaceutical companies and the U.S. FDA. Nordic Capital, a Stockholm-based private equity firm, acquired ArisGlobal in 2019 for approximately $700 million. The company has reported revenues of approximately €150 million as of 2025, reflecting significant growth under PE ownership — including a near-doubling of profit in the two years following Nordic’s initial acquisition.
For Dassault Systèmes, whose core business is 3D design and simulation software for industries like aerospace and manufacturing, life sciences has become the most strategically significant growth vertical. The company’s 3DEXPERIENCE platform is already used by pharma and biotech clients for molecule modeling and virtual clinical trials via Medidata. Folding in ArisGlobal’s regulatory, safety, and medical affairs software would give Dassault a more comprehensive suite spanning both the experimental and regulatory dimensions of drug development — a combination few software vendors can offer at scale. The implied valuation of roughly $2 billion represents a meaningful step up from ArisGlobal’s 2019 acquisition price and reflects both its revenue growth and the premium placed on life sciences software platforms in the current M&A market.
Nordic Capital, with approximately €30 billion in assets under management, has been one of the most active private equity investors in healthcare technology in Europe and North America. Its exit from ArisGlobal, if completed, would represent one of the firm’s most significant healthcare software realizations.
